• Over 25 years of experience in investment banking • Previously worked at JP Morgan Chase and Goldman Sachs • BS and MBA from Harvard University
Mr. Wang has 25 years of investment banking experience and is widely recognized as one of the most influential figures and pioneers in China's investment banking industry. He founded CEC Capital Group (formerly known as China eCapital Group) in 2000 and is now chairman and CEO of the firm. Under his leadership, CEC Capital, which has closed over 500 transactions with total deal value exceeding RMB500 billion, has emerged as a leading private investment bank and asset management firm with a core focus on the TMT, consumer and healthcare sectors. Mr. Wang started his investment banking career at Goldman Sachs in 1994. Prior to founding CEC Capital, he had spent the previous three years with the Global M&A Group of JP Morgan, where he was responsible for developing and executing a number of large M&A transactions in the Asia-Pacific region. Mr. Wang has a bachelor degree in economics from Harvard College and an MBA from Harvard Business School. He has published extensively in leading Chinese financial press.
• Over 20 years of experience in investment banking and the healthcare industry • Previously worked at Merck and Accenture • BS in Mechanical Engineering and MBA from U.C. Berkeley
Ms. Hong is a founding partner for CEC Capital Group, and leads the healthcare industry group. Under her guidance, CEC Capital has emerged as a leader in the healthcare industry with the largest specialized team of over 50 dedicated healthcare bankers, covering pharma/biotech, medical device, services, digital healthcare, and synthetic biology sectors. CEC works with leading China healthcare players and also has a strong cross-border practice. Prior to joining CEC Capital, Ms. Hong was with Accenture Strategic Services (formerly Andersen Consulting) in San Francisco. Before receiving her MBA, Ms. Hong worked as an engineer for Merck and worked on several significant projects, including a humanitarian technology transfer of a Recombinant Hepatitis B vaccine to China, and the launch of Crixivan, a protease inhibitor for HIV. Ms. Hong has both her MBA and BS in Mechanical Engineering from UC Berkeley.
• Over 10 years experience in investment banking • Previously worked at IBD, CITIC Securities • Master in Finance and Financial Management from Berlin School of Economics and Law
Mr. Li once served as the Senior Vice President at CITIC Securities and participated in various projects covering refinancing, overseas M&A, asset restructuring and financial advising services. Since 2012, he has been focusing on the medical and healthcare industry. He has provided a full range of investment banking services for many distinguished companies such as Dianhong Pharmaceutical, Yiling Pharmaceutical, Yifeng Pharmacy, Shineway Pharmaceutical, Jointown Pharmaceutical and Huahai Pharmaceutical. During his tenure in CITIC Securities, he also directly promoted and participated in the establishment and implementation of several fund and asset management programs. Mr. Li holds a Master’s degree in International Finance and Finance Management from the Berlin School of Economics and Law, and is fluent in German and English.
• Over 10 years of experience in investment management • Previously worked at FountainVest Partners and the New York City Employee Retirement System • BS from New York University Stern School of Business and LLM from Peking University Law School
Mr. Xu is a partner of CEC Capital and is the Managing Partner of CEC Future Industry Private Equity Fund. In his over ten-year career as a professional investor, Mr. Xu has managed more than USD 4 billion globally. He started his investment career in 2006 at the New York City Employee Retirement System, which managed USD 220 billion, and was responsible for their emerging market private equity investments. Before joining CEC Capital, Mr. Xu worked at FountainVest Partners, one of the largest private equity funds in China. Mr. Xu holds a Bachelor’s degree from New York University’s Stern School of Business and an LLM from Peking University Law School.
• Over 10 years of investment and management experience in entertainments, sports, TMT, and the consumer industry • Previously worked at Fosun, Roland Berger and General Mills • BS from Ohio State University and MBA from Oxford University
As a veteran investor, Mr. Wang has rich experience in domestic and foreign investment, management consulting and business operations. His career began at the US-based General Mills, where he participated in and completed the largest M&A transactions in the company’s history. After returning to China, he worked at Roland Berger as a senior consultant in consumer goods, healthcare and other industries. In 2010, Mr. Wang joined CEC Capital and during the four years spent here, he completed financing and M&A transactions worth over RMB 10 billion before leaving as the senior director of M&A. In 2014, he joined the Fosun Group where he served as the Executive Director of International Development Department and China Momentum Fund and led a number of investments in Infront Sports & Media, DTZ Zadelhoff, and other companies. In 2016, he returned to CEC and as a founder of the RMB fund, where he serves as a fund partner and member of the Investment Committee. Mr. Wang holds an MBA from Oxford University and a BS degree in Management from Ohio State University.
• Over 15 years of experience in healthcare industry, investment and M&A. • Worked for GSK, Mindray, ASB Ventures, and BGI Co-win • Master of Biochemistry and Molecular Biology from Sun Yat-sen University, MBA from Peking University.
Mr. Li Jin is a Partner at CEC Capital and Head of the Medtech Division. Since joining CEC Capital in 2020, Mr. Li has led the team to complete numerous financing transactions in Medtech, including notable deals such as WuXi Diagnostics, GenomePrecision Tech, b-ONE, NuProbe, Visionmedicals, and UnionStrong Tech. Before joining CEC Capital, he worked for BGI Co-win, focusing on private equity investments.
• 10+ years of experience in the healthcare industry, including investment and investment banking • Previously worked at Beijing Jishuitan Hospital, VAMED, Concord Holdings, ZY Medical Investment, cn-healthcare.com, and Silver Mountain Capital • Holds a Bachelor's degree in Clinical Medicine from Shanghai Medical College, Fudan University, and an MBA from the University of Illinois at Chicago
Mr. Bin Wang is currently serving as the Managing Director and Head of the Healthcare Services Team at CEC Capital. Since joining CEC Capital in 2018, Mr. Wang has demonstrated a profound understanding and extensive coverage of the healthcare services sector, leading the team to complete numerous financing transactions for companies such as Sanbo Brain Hospital, Tencent Doctor Work, Laoken Medical, Sunny Dental, Shanghai Donglei Brain Hospital, EverCare, Nubo Medical, Left Hand Doctor, Diagens. Prior to joining CEC Capital, he worked at Silver Mountain Capital, focusing on private equity investments.
• Years of experience in the Synthetic Biology industry and investment sector • Previously worked at NIH-NIEHS, Chinese Academy of Sciences (CAS), BGI Genomics, Hongtai Aplus, CAS VENTURE CAPITAL, and Cash Capital • Holds a Ph.D. in Biophysics from the Institute of Biophysics, Chinese Academy of Sciences
Ms. Jieying Liao is currently serving as the Managing Director and Head of the Synthetic Biology Team at CEC Capital. She specializes in serving companies in the Synthetic Biology sector and related upstream and downstream industries. With a diverse background in research, industry, and investment, Ms. Liao has been instrumental in private equity investments in the healthcare industry at Cash Capital, representing projects such as Mabworks Biotech, Thousand Oaks Biologics, INNOGEN, RNACure, TIAN JIAN, Biocreatech and CASMN.
• Over 10 years of experience in PE investment and management • Nearly 10 years of experience in Secondary Fund, with a cumulative fund management scale exceeding RMB 5 billion • Previously worked at Gopher Asset, Five Star Holdings Group, and China Renaissance as the head of Secondary Fund • Holds a EMBA in SAIF of SJTU; Bachelor of Statistics in SUFE
Mr. Yuan Ye is currently serving as the Managing Director and the Head of GPLP Investment and Exit Services (S Fund Partner) at CEC Capital. Prior to this, he had previously worked at Gopher Asset, Five Star Holdings Group, and China Renaissance as the head of S Fund, and had earlier established the investment methodology and valuation system of S Fund in China. Mr. Yuan Ye is very familiar with the domestic GP&LP ecosystem. He has invested in more than 30 domestic GP’s fund shares, including Sequoia, Dachen, Matrix, StoneVC and etc. He has also led several complex Secondary deals, in forms of tender offering, portfolio transaction, structured financing and etc.
• Over fifteen years of domestic and overseas investment banking experience, with in-depth coverage of the consumer industry • Familiar with domestic and overseas capital markets, led many A-share and Hong Kong private placements, IPOs, follow-ons, bond issuances and (cross-border) M&A projects • Previously worked in J.P. Morgan, China Renaissance Securities, CITIC Securities and Ping An Securities • Master of Finance from Shanghai Jiao Tong University; Bachelor of Finance from East China University of Science and Technology
Mr. Zhang Xun is currently serving as the Managing Director and Head of Consumer team at CEC Capital. Before joining CEC Capital, he worked in the investment banking departments of J.P. Morgan, China Renaissance Securities, CITIC Securities and Ping An Securities, and has been deeply involved in the consumer industry investment banking business for more than ten years. Mr. Zhang Xun is very familiar with various products in domestic and overseas capital markets, and has been responsible for many private placements, IPOs, follow-ons, bond issuances and (cross-border) M&A projects for onshore/offshore listed/private clients.
•Years of experience in capital markets and large enterprise groups •Worked for Zero2IPO Group and Aimer Group •Master of Economics, Renmin University of China
Ms. Maggie Qi is the head of the ECM of CEC Capital and has nearly ten years of investment bank experience in capital markets. Its team has the ability to cover more than 6,000 different types of investors at home and abroad, and provides in-depth services of "capital + industry" for customers in different fields of service, including equity financing, debt financing, industry landed in the local, and domestic and foreign business expansion. Ms. Maggie Qi has accumulated many years of in-depth coverage and cooperation experience in the fields of national background/government background investment institutions, listed companies, large enterprise groups, state enterprise and VC/PE. Led and finished: 4Paradigm、Sunwoda、BIRENTECH、SPICHE、汇付天下、AutoX、Lenovo and other leading enterprise.
Please visit our official website www.ceccapitalus.com
.